MarketCap
Facebook
X
Telegram
SpringWorks Therapeutics Operating Cycle | SWTX
Annual Operating Cycle SpringWorks Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 243 | 1.54 K | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.54 K | 243 | 892 |
Quarterly Operating Cycle SpringWorks Therapeutics
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 373 | - | 293 | 271 | 362 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 373 | 271 | 325 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Codexis
CDXS
|
70.7 | $ 0.97 | -2.6 % | $ 84.5 M |  USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Biogen
BIIB
|
402 | $ 254.59 | 0.53 % | $ 37.3 B | USA |
 |
GlaxoSmithKline plc
GSK
|
0.04 | $ 50.63 | -1.18 % | $ 205 B |  Britain |
 |
Edesa Biotech
EDSA
|
97.1 | $ 2.26 | 11.88 % | $ 12.8 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
408 | $ 15.2 | 0.66 % | $ 983 M | USA |
 |
Fulcrum Therapeutics
FULC
|
6.75 | $ 3.74 | 0.54 % | $ 237 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
259 | $ 28.37 | 0.62 % | $ 4.54 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
214 | $ 8.09 | 0.06 % | $ 2.89 M | USA |
 |
Evogene Ltd.
EVGN
|
30 | $ 0.37 | -0.51 % | $ 2.91 M |  Israel |
 |
Axsome Therapeutics
AXSM
|
273 | $ 148.5 | 5.34 % | $ 7.39 B | USA |
 |
Champions Oncology
CSBR
|
74.9 | $ 4.77 | 0.42 % | $ 66 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
148 | $ 10.7 | 1.13 % | $ 306 M | USA |
 |
Longeveron
LGVN
|
28.6 | $ 3.27 | 15.14 % | $ 57.5 B | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.85 | 1.03 % | $ 6.02 B |  Spain |
 |
Incyte Corporation
INCY
|
145 | $ 122.28 | 1.65 % | $ 23.9 B | USA |
 |
AIM ImmunoTech
AIM
|
14.5 | $ 0.15 | 6.3 % | $ 243 K | USA |
 |
MediWound Ltd.
MDWD
|
78.7 | $ 13.81 | -2.13 % | $ 376 M | Israel |
 |
ANI Pharmaceuticals
ANIP
|
254 | $ 71.09 | -0.22 % | $ 1.43 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
129 | $ 1.24 | -6.06 % | $ 330 M | Britain |
 |
BioCryst Pharmaceuticals
BCRX
|
168 | $ 7.66 | 1.73 % | $ 1.61 B | USA |
 |
Coherus BioSciences
CHRS
|
656 | $ 0.58 | -8.97 % | $ 67.9 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
291 | $ 28.37 | 3.6 % | $ 3.61 B | USA |
 |
Cellectis S.A.
CLLS
|
136 | $ 1.35 | 21.62 % | $ 135 M |  France |
 |
Alkermes plc
ALKS
|
441 | $ 47.94 | 3.16 % | $ 7.9 B |  Irlanda |
 |
Altimmune
ALT
|
7.85 K | $ 1.94 | -0.21 % | $ 171 M | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 0.76 | -4.57 % | $ 50.8 M | USA |
 |
Novartis AG
NVS
|
0.04 | $ 160.35 | -1.79 % | $ 311 B |  Schweiz |
 |
Arrowhead Pharmaceuticals
ARWR
|
1.5 | $ 49.35 | 0.71 % | $ 6.6 B | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
659 | $ 16.22 | -0.49 % | $ 2.18 B |  Canada |